EUVIMEDEUVIMED entdecken
Crossref

Hydrocolloid matrix systems for modified release of diltiazem hydrochloride: A step toward personalized cardiovascular therapy

Nadezhda Ivanova, Sylvia Stamova, Velichka Andonova

Scripta Scientifica Medica · 2026

DOI: 10.14748/8ag18j40 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scripta Scientifica Medica, 2026. Verfasst von Nadezhda Ivanova und 2 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sustained-release dosage forms represent a valuable tool in the pharmaceutical development of drugs with high water solubility and a short biological half-life (t₁/₂), as they help optimize dosing regimens and improve therapeutic efficacy. Hydrocolloid matrices offer a practical solution for controlling drug release through swelling and erosion, thus ensuring prolonged dissolution and diffusion of the active substance.

Aim

This study aimed to investigate various hydrocolloid matrices as sustained drug delivery platforms for diltiazem. Materials and Methods: Diltiazem hydrochloride, a highly water-soluble and biochemically unstable drug with a short half-life (3.5–4 h), was formulated into hydrocolloid matrix tablets composed of hydroxypropyl methylcellulose (HPMC), sodium carboxymethylcellulose (CMC-Na), or a 1:1 combination of the two cellulose derivatives. The different hydrocolloid formulations were subjected to pharmacopoeial dissolution and swelling studies in simulated gastric fluid (HCL 0.1 M) and simulated intestinal fluid (phosphate buffer saline—PBS, pH 6.8).

Results

Pronounced differences were observed in the in vitro behavior of the matrices in PBS 6.8, where the highest swelling index was recorded for the CMC-Na matrix (476.9%), followed by the combined HPMC:CMC-Na matrix (323.3%) and the HPMC matrix (104.0%). Increased swelling was associated with slower drug release, indicating that extension of the diffusion pathway represented the dominant release-controlling mechanism.

Conclusion

This study provides an in vitro comparison of three hydrocolloid models for the sustained delivery of diltiazem, enabling formulation optimization according to specific therapeutic goals and supporting the development of personalized dosage forms (e.g., through 3D printing technologies).

Zitieren

APA

Ivanova, N., Stamova, S., & Andonova, V. (2026). Hydrocolloid matrix systems for modified release of diltiazem hydrochloride: A step toward personalized cardiovascular therapy. Scripta Scientifica Medica. https://doi.org/10.14748/8ag18j40

Vancouver

Ivanova N, Stamova S, Andonova V. Hydrocolloid matrix systems for modified release of diltiazem hydrochloride: A step toward personalized cardiovascular therapy. Scripta Scientifica Medica. 2026. doi:10.14748/8ag18j40

BibTeX
@article{Ivanova2026,
  author = {Ivanova, Nadezhda and Stamova, Sylvia and Andonova, Velichka},
  title = {Hydrocolloid matrix systems for modified release of diltiazem hydrochloride: A step toward personalized cardiovascular therapy},
  journal = {Scripta Scientifica Medica},
  year = {2026},
  doi = {10.14748/8ag18j40}
}
Kostenlos starten →